References
- Aymard G, Warot D, Démolis P, et al. (2003). Comparative pharmacokinetics and pharmacodynamics of intravenous and oral nefopam in healthy volunteers. Pharmacol Toxicol 92:279–86
- Bolt AG, Graham G, Wilson P. (1974). Stereoselective demethylation of the enantiomers of nefopam, an experimental antidepressant and skeletal muscle relaxant. Xenobiotica 4:355–63
- Chawla J, Le Guern ME, Alquier C, et al. (2003). Effect of route of administration on the pharmacokinetic behavior of enantiomers of nefopam and desmethylnefopam. Ther Drug Monit 25:203–10
- Dell'Osso B, Buoli M, Baldwin DS, Altamura AC. (2010). Serotonin norepinephrine reuptake inhibitors (SNRIs) in anxiety disorders: a comprehensive review of their clinical efficacy. Hum Psychopharmacol 25:17–29
- Evans MS, Lysakowski C, Tramer MR. (2008). Nefopam for the prevention of postoperative pain: quantitative systematic review. Br J Anaesth 101:610–17
- Girard P, Coppé MC, Verniers D, et al. (2006). Role of catecholamines and serotonin receptor subtypes in nefopam-induced antinociception. Pharmacol Res 54:195–202
- Heel RC, Brogden RN, Pakes GE, et al. (1980). Nefopam: a review of its pharmacological properties and therapeutic efficacy. Drugs 19:249–67
- Hop CE, Wang Z, Chen Q, Kwei G. (1998). Plasma-pooling methods to increase throughput for in vivo pharmacokinetic screening. J Pharm Sci 87:901–3
- Houston JB, Taylor G. (1984). Drug metabolite concentration–time profiles: influence of route of drug administration. Br J Clin Pharmacol 17:385–94
- Hunskaar S, Fasmer OB, Broch OJ, Hole K. (1987). Involvement of central serotonergic pathways in nefopam-induced antinociception. Eur J Pharmacol 138:77–82
- Kapfer B, Alfonsi P, Guignard B, et al. (2005). Nefopam and ketamine comparably enhance postoperative analgesia. Anesth Analg 100:169–74
- Kirchherr HJ, Christ W. (1984). Nefopam and N-desmethyl-nefopam: activity in the hot plate and writhing test. Naunyn Schmiedebergs Arch Pharmacol 325:R72
- Lee YC, Chen PP. (2010). A review of SSRIs and SNRIs in neuropathic pain. Expert Opin Pharmacother 11:2813–25
- Mimoz O, Chauvet S, Grégoire N, et al. (2010). Nefopam pharmacokinetics in patients with end-stage renal disease. Anesth Analg 111:1146–53
- Mulder GJ. (1992). Glucuronidation and its role in regulation of biological activity of drugs. Annu Rev Pharmacol Toxicol 32:25–49
- Novelli A, Diaz-Trelles R, Groppetti A, Fernandez-Sanchez MT. (2005). Nefopam inhibits calcium influx, cGMP formation, and NMDA receptor-dependent neurotoxicity following activation of voltage sensitive calcium channels. Amino Acids 28:183–91
- Rydberg P, Gloriam DE, Zaretzki J, et al. (2010). SMARTCyp: a 2D method for prediction of cytochrome P450-mediated drug metabolism. ACS Med Chem Lett 1:96–100
- Taylor D, Lenox-Smith A, Bradley A. (2013). A review of the suitability of duloxetine and venlafaxine for use in patients with depression in primary care with a focus on cardiovascular safety, suicide and mortality due to antidepressant overdose. Ther Adv Psychopharmacol 3:151–61
- Thase ME. (2008). Are SNRIs more effective than SSRIs? A review of the current state of the controversy. Psychopharmacol Bull 41:58–85
- Verleye M, André N, Heulard I, Gillardin JM. (2004). Nefopam blocks voltage-sensitive sodium channels and modulates glutamatergic transmission in rodents. Brain Res 1013:249–55